The common types of lung cancer gene mutations mainly include epidermal growth factor receptor gene mutation, echinoderm-like microtubule-associated-like egg-4 mesenchymal lymphoma kinase fusion gene mutation, and hepatocyte growth factor tyrosine kinase receptor gene mutation. 1. Epidermal growth factor gene mutation (EGFR): the mutation mainly occurs in the exon of chromosome 18-21. Mutations lead to abnormalities in the activity of the gene, resulting in the development of the disease. Targeted drugs for this gene are mainly erlotinib, gefitinib and afatinib. 2. Echinoderm-like microtubule-associated-like egg 4-mesenchymal lymphoma kinase fusion gene mutation (EML4-ALK): It is common in young, nonsmoking or low-smoking non-small cell lung cancer patients. Mutations in this gene affect cell proliferation, differentiation and apoptosis. Targeted drugs for this gene are mainly colored ritinib and erlotinib. 3. Hepatocyte growth factor tyrosine kinase receptor gene mutation (MET gene mutation): this is a proto-oncogene. The mutation often occurs in the exon of chromosome 14, which leads to the continuous activation of the gene, resulting in the development of lung cancer. Targeted drugs for this gene mutation mainly include Carmatinib. For patients diagnosed with lung cancer, they should go to the relevant departments of regular hospitals as soon as possible and under the guidance of professional physicians to avoid delays.